abstract: AIM: The objective of this study was to examine perinatal and neonatal properties of preterm @entity1 with a corrected age of 24-36 months who were born as a result of spontaneous and in vitro fertilization @entity2099 , to interrogate somatic growth properties of these @entity1 and evaluate the factors which had an impact by comparing groups. MATERIAL AND METHODS: A total of 125 @entity1 with a birth weight below 2 500 g and a gestational age below the 37(th) gestational week 60 of whom were born as a result of in vitro fertilization @entity2099 and 65 of whom were born as a result of spontaneous @entity2099 were included in the study. Maternal age and morbidity, early rupture of membranes, birth weigth, gestational week, gender, APGAR score, hospitalization reasons in the neonatal period, requirement for intensive care, frequency of @entity154 , outpatient follow-up status, rehospitalization and socioeconomic levels were interrogated in the @entity1 . Detailed physical examination and current height, weight and head circumference measurements were performed and the findings were placed in the growth curves of Neyzi et al. Ethics committee approval was received for this study from the ethics committee of @entity2428  rk  y Gynecology Obstetrics and Pediatrics Education and Research Hospital (12.10.2010; no:305). RESULTS: The rate of cesarean section, mean maternal age, the rate of @entity102 in the mother and the rate of maternal disease which occured during pregnancy were significantly higher in the in vitro fertilization group (p<0.05). While no difference was found in mean gestational age, birth weight, rate of hospitalization, time of hospitalization, frequency of follow-up in the intensive care unit, rates of @entity154 and rehospitalization, APGAR score in the 5(th) minute was significantly higher in the in vitro fertilization group. The socioeconomical score was not different between the groups, but the in vitro fertilization group presented more regularly for outpatient follow-up visits. Height, head circumference measurements and mean current weight were found to be significantly higher in the in vitro fertilization group (p<0.05). CONCLUSION: The fact that there was no difference in the rate of hospitalization, time of hospitalization, frequency of follow-up in the intensive care unit, rates of @entity154 and rehospitalization was attributed to the fact that the study and control groups were composed of only @entity2099 and preterms.

title: Perinatal and somatic growth properties of preterm babies born from spontaneous and in vitro fertilization XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients', 'infants']

entities_list: @entity154 :: ('MESH:D000013', 'Disease') :: ['congenital anomaly']

entities_list: @entity102 :: ('MESH:D002908', 'Disease') :: ['chronic disease']

entities_list: @entity2099 :: ('MESH:D011254', 'Disease') :: ['multiple pregnancies']

answer: @entity2099 :: (MESH:D011254,Disease) :: ['multiple pregnancies']


abstract: UNASSIGNED: Introduction. @entity162 ( @entity162 ) implies risk of suicide. The age at onset (AAO) of @entity162 carries prognostic significance. @entity734 may precede the onset of @entity162 and @entity835 is the most common illicit drug used. The main goal of this study is to review the association of @entity835 use as a risk factor for early onset of @entity162 and for suicide attempts. Materials and Methods. PubMed database was searched for articles using key words " @entity162 ," "suicide attempts," " @entity835 ," " @entity835 ," "early age at onset," and "early onset." Results. The following percentages in @entity162 @entity1 were found: suicide attempts 3.6-42%; suicide attempts and substance use 5-60%; suicide attempts and @entity835 use 15-42%. An early AAO was associated with @entity835 misuse. The mean age of the first @entity162 in individuals with and without @entity162 and @entity835 ( @entity835 ) was 19.5 and 25.1 years, respectively. The first @entity308 was at 18.5 and 24.4 years, respectively. Individuals misusing @entity835 showed increased risk of suicide. Discussion. Cannabis use is associated with increased risk of suicide attempts and with early AAO. However, the effect of @entity835 at the AAO and suicide attempts is not clear.

title: The Use of Cannabis as a Predictor of Early Onset of XXXX and Suicide Attempts.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity162 :: ('MESH:D001714', 'Disease') :: ['bipolar disorder', 'BD', 'manic episode', 'Bipolar disorder', 'bipolar']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depressive episode']

entities_list: @entity835 :: ('MESH:D002189', 'Disease') :: ['CUD', 'cannabis', 'marijuana', 'cannabis use disorder']

entities_list: @entity734 :: ('MESH:D019966', 'Disease') :: ['Substance abuse']

answer: @entity162 :: (MESH:D001714,Disease) :: ['Bipolar Disorder']


abstract: BACKGROUND: @entity1494 is a rare @entity154 seen in 2.15 @entity1 out of every 100,000 live births, with the most severe variant, @entity7891 ( @entity7891 ), only occurring in 1 in 200,000. @entity572 ( @entity572 ) describes a spectrum of disease ranging from mild hip instability to @entity3029 . Underlying @entity600 , such as @entity9960 and @entity8482 , are often associated with the most severe variant of @entity572 , teratologic @entity572 . The varying degrees of severity in @entity572 have been encountered in classic @entity1494 (CBE) @entity1 , but the exact incidence is unknown. We sought to determine the incidence of @entity572 in CBE and @entity7891 @entity1 . METHODS: We performed a retrospective review of all @entity1 with CBE or @entity7891 presenting to a single pediatric center between 1994 and 2014. Each chart was reviewed for correct diagnosis of CBE or @entity7891 , @entity1 age and demographics, associated medical conditions, pertinent surgeries performed, and the age at operation. @entity1 imaging was reviewed to determine whether bilateral hip imaging was available. RESULTS: In a 20-year retrospective review, we identified 66 @entity1 who were diagnosed with either CBE or @entity7891 and had available hip imaging (38 males and 28 females). Of these, 11 @entity1 were found to have radiographic evidence of @entity572 , for an incidence of 16.7% (11/66). Five of these @entity1 had @entity7891 , whereas 6 presented with CBE. The first radiographic evidence of @entity572 was noted at a mean age of 5.75 years (range, birth to 22 y). CONCLUSIONS: We advocate the use of routine hip screening ultrasound in all @entity1 born with either CBE or @entity7891 . Early identification of @entity572 in these @entity1 may allow additional treatment options to coincide with frequently used osteotomy and orthopaedic interventions. LEVEL OF EVIDENCE: Level III-retrospective study.

title: Incidence of XXXX Associated With @entity1494 .

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients', 'patient', 'infants', 'Patient']

entities_list: @entity154 :: ('MESH:D000013', 'Disease') :: ['congenital defect']

entities_list: @entity1494 :: ('MESH:D001745', 'Disease') :: ['bladder exstrophy', 'Exstrophy of the bladder']

entities_list: @entity8482 :: ('MESH:D001176', 'Disease') :: ['arthrogryposis']

entities_list: @entity600 :: ('MESH:D000014', 'Disease') :: ['malformations']

entities_list: @entity9960 :: ('MESH:D008591', 'Disease') :: ['myelomeningocele']

entities_list: @entity7891 :: ('MESH:D001746', 'Disease') :: ['CE', 'cloacal exstrophy']

entities_list: @entity572 :: ('MESH:D006617', 'Disease') :: ['hip dislocation', 'DDH', 'hip dysplasia', 'Developmental dysplasia of the hip']

entities_list: @entity3029 :: ('MESH:D004204', 'Disease') :: ['frank dislocation']

answer: @entity572 :: (MESH:D006617,Disease) :: ['Hip Dysplasia']


abstract: BACKGROUND: @entity1494 is a rare @entity154 seen in 2.15 @entity1 out of every 100,000 live births, with the most severe variant, @entity7891 ( @entity7891 ), only occurring in 1 in 200,000. @entity572 ( @entity572 ) describes a spectrum of disease ranging from mild hip instability to @entity3029 . Underlying @entity600 , such as @entity9960 and @entity8482 , are often associated with the most severe variant of @entity572 , teratologic @entity572 . The varying degrees of severity in @entity572 have been encountered in classic @entity1494 (CBE) @entity1 , but the exact incidence is unknown. We sought to determine the incidence of @entity572 in CBE and @entity7891 @entity1 . METHODS: We performed a retrospective review of all @entity1 with CBE or @entity7891 presenting to a single pediatric center between 1994 and 2014. Each chart was reviewed for correct diagnosis of CBE or @entity7891 , @entity1 age and demographics, associated medical conditions, pertinent surgeries performed, and the age at operation. @entity1 imaging was reviewed to determine whether bilateral hip imaging was available. RESULTS: In a 20-year retrospective review, we identified 66 @entity1 who were diagnosed with either CBE or @entity7891 and had available hip imaging (38 males and 28 females). Of these, 11 @entity1 were found to have radiographic evidence of @entity572 , for an incidence of 16.7% (11/66). Five of these @entity1 had @entity7891 , whereas 6 presented with CBE. The first radiographic evidence of @entity572 was noted at a mean age of 5.75 years (range, birth to 22 y). CONCLUSIONS: We advocate the use of routine hip screening ultrasound in all @entity1 born with either CBE or @entity7891 . Early identification of @entity572 in these @entity1 may allow additional treatment options to coincide with frequently used osteotomy and orthopaedic interventions. LEVEL OF EVIDENCE: Level III-retrospective study.

title: Incidence of @entity572 Associated With XXXX .

answer: @entity1494 :: (MESH:D001745,Disease) :: ['Bladder Exstrophy']


abstract: BACKGROUND: Surgical treatment is recommended for @entity1 with unstable @entity1843 ( @entity1843 ) of the elbow. However, little information is available comparing the anticipated results from the host of techniques. In this investigation, clinical and radiographic resolution as well as return to sports rates were assessed in adolescent @entity1 following loose body (LB) removal and drilling/microfracture of grade IV lesions. METHODS: We reviewed 21 adolescents treated with LB removal and drilling/microfracture for grade IV elbow @entity1843 . @entity1 with additional elbow pathology, prior elbow surgery, or <1 year follow-up were excluded. Clinical resolution was defined as resolution of tenderness and radiographic resolution as resolution of @entity4 on magnetic resonance imaging (MRI). Return to sport rates and Timmerman scores were assessed. Mean clinical and MRI follow-up times were 2.2  1.19 and 2.4  1.54 years, respectively. Clinical and radiographic parameters associated with clinical and/or radiographic resolution or return to sports were determined using penalized likelihood logistic regression. Wilcoxon signed-rank tests were used to evaluate the change in range of motion and in Timmerman scores. RESULTS: Fifteen (71.4%) @entity1 had either clinical or radiographic resolution at most recent follow-up. Nine (50%) had complete resolution on MRI, whereas 13 (61.9%) were nontender at their follow-up. Four @entity1 with recurrent LBs underwent revision surgery. There were no complications in the 21 index procedures. Eighteen (85.7%) @entity1 returned to any sport, whereas 14 (66. 7%) returned to their primary sport. Elbow flexion and extension improved by medians of 12 and 21 degrees, respectively (P=0.002, 0.01). Timmerman scores improved by a median of 30 (P=0.001). Shorter duration of symptoms correlated with @entity1843 (P=0.03) and with improved clinical or radiographic resolution and return to sport rates. CONCLUSIONS: The majority of @entity1 with grade IV elbow @entity1843 achieves clinical and/or radiographic resolution and return to sports 2 years after LB removal and drilling/microfracture. Recurrence may be seen, however, and further investigation is needed to assess the efficacy of this technique compared with other treatment strategies. LEVEL OF EVIDENCE: Level IV.

title: Early Results of Drilling and/or Microfracture for Grade IV XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity1843 :: ('MESH:D010008', 'Disease') :: ['OCD', 'smaller OCD lesions', 'osteochondritis dissecans']

answer: @entity1843 :: (MESH:D010008,Disease) :: ['Osteochondritis Dissecans of the Capitellum']


abstract: BACKGROUND AND OBJECTIVES: @entity1371 has been consistently associated with high mortality rate in peritoneal dialysis. However, studies investigating if @entity1371 is acting as a surrogate marker of comorbidities or has a direct effect in the risk for mortality have not been studied. Thus, the aim of this study was to analyze the effect of @entity1371 on overall and cause-specific mortality. DESIGN, SETTING, @entity1 AND MEASUREMENTS: This is an analysis of BRAZPD II, a nationwide prospective cohort study. All @entity1 on @entity1726 for longer than 90 days with measured serum @entity972 levels were used to verify the association of @entity1371 with overall and cause-specific mortality using a propensity match score to reduce selection bias. In addition, competing risks were also taken into account for the analysis of cause-specific mortality. RESULTS: There was a U-shaped relationship between time-averaged serum @entity972 and all-cause mortality of @entity1726 @entity1 . @entity65 was the main cause of @entity204 in the normokalemic group with 133 events (41.8%) followed by @entity281 , n=105 (33.0%). @entity1371 was associated with a 49% increased risk for CV mortality after adjustments for covariates and the presence of competing risks (SHR 1.49; CI95% 1.01-2.21). In contrast, in the group of @entity1 with K <3.5mEq/L, @entity281 were the main cause of @entity204 with 43 events (44.3%) followed by @entity65 (n=36; 37.1%). For @entity281 the SHR was 2.19 (CI95% 1.52-3.14) while for @entity298 was SHR 1.09 (CI95% 0.47-2.49). CONCLUSIONS: @entity1371 had a significant impact on overall, cardiovascular and infectious mortality even after adjustments for competing risks. The causative nature of this association suggested by our study raises the need for intervention studies looking at the effect of @entity972 supplementation on clinical outcomes of @entity1726 @entity1 .

title: Low Serum XXXX Levels Increase the Infectious-Caused Mortality in Peritoneal Dialysis @entity1 : A Propensity-Matched Score Study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PARTICIPANTS']

entities_list: @entity298 :: ('MESH:D010538', 'Disease') :: ['peritonitis']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['PD-non related infections']

entities_list: @entity972 :: ('MESH:D011188', 'Chemical') :: ['potassium']

entities_list: @entity1371 :: ('MESH:D007008', 'Disease') :: ['hypokalemia', 'Hypokalemia']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['Cardiovascular disease', 'cardiovascular disease']

answer: @entity972 :: (MESH:D011188,Chemical) :: ['Potassium']


abstract: BACKGROUND AND OBJECTIVES: @entity1371 has been consistently associated with high mortality rate in peritoneal dialysis. However, studies investigating if @entity1371 is acting as a surrogate marker of comorbidities or has a direct effect in the risk for mortality have not been studied. Thus, the aim of this study was to analyze the effect of @entity1371 on overall and cause-specific mortality. DESIGN, SETTING, @entity1 AND MEASUREMENTS: This is an analysis of BRAZPD II, a nationwide prospective cohort study. All @entity1 on @entity1726 for longer than 90 days with measured serum @entity972 levels were used to verify the association of @entity1371 with overall and cause-specific mortality using a propensity match score to reduce selection bias. In addition, competing risks were also taken into account for the analysis of cause-specific mortality. RESULTS: There was a U-shaped relationship between time-averaged serum @entity972 and all-cause mortality of @entity1726 @entity1 . @entity65 was the main cause of @entity204 in the normokalemic group with 133 events (41.8%) followed by @entity281 , n=105 (33.0%). @entity1371 was associated with a 49% increased risk for CV mortality after adjustments for covariates and the presence of competing risks (SHR 1.49; CI95% 1.01-2.21). In contrast, in the group of @entity1 with K <3.5mEq/L, @entity281 were the main cause of @entity204 with 43 events (44.3%) followed by @entity65 (n=36; 37.1%). For @entity281 the SHR was 2.19 (CI95% 1.52-3.14) while for @entity298 was SHR 1.09 (CI95% 0.47-2.49). CONCLUSIONS: @entity1371 had a significant impact on overall, cardiovascular and infectious mortality even after adjustments for competing risks. The causative nature of this association suggested by our study raises the need for intervention studies looking at the effect of @entity972 supplementation on clinical outcomes of @entity1726 @entity1 .

title: Low Serum @entity972 Levels Increase the Infectious-Caused Mortality in Peritoneal Dialysis XXXX : A Propensity-Matched Score Study.

answer: @entity1 :: (9606,Species) :: ['Patients']


abstract: UNASSIGNED: @entity455 following arthroscopic anterior cruciate ligament (ACL) reconstruction of the knee are rare. @entity1545 around the knee have historically been reported more commonly, with reconstructive procedures occurring more posteriorly, such as posterior cruciate ligament (PCL) reconstruction. The authors present a report of sequelae following a @entity86 in an 18-year-old female soccer player who underwent ACL reconstruction using an ipsilateral autologous hamstring graft along with a medial meniscal repair and developed immediate @entity2473 of the popliteal artery responding to sustained balloon angioplasty. Seven weeks postoperatively, she developed foot paresthesias and was noted to have a 3.5*3.1*1.3-cm @entity2849 of her popliteal artery. She underwent popliteal artery bypass with reverse saphenous vein autograft and had an uneventful recovery. This case highlights the importance of prolonged follow-up and maintaining a high degree of @entity455 , even after routine arthroscopic knee procedures. In addition to maintaining close and extended follow-up, the authors agree with other authors' suggestions that urgent computed tomography angiogram be obtained to evaluate the vascular tree in a @entity1 presenting with a cold, @entity12040 after routine arthroscopic knee procedures. In this particular case, angiography of the uninvolved side also proved useful in identifying the @entity1 's aberrant vascular anatomy and may be useful in @entity1 with bilateral aberrant vascular anatomy to better facilitate interpretation of the injured side. To the author's knowledge, this is the first case of popliteal artery @entity2473 initially responding to sustained angioplasty with the delayed development of a @entity2849 . [Orthopedics. 2015; 38(6):e543-e546.].

title: Delayed XXXX of the Popliteal Artery Following ACL Reconstruction.

entities_list: @entity1545 :: ('MESH:D020214', 'Disease') :: ['Injuries to vascular structures']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity455 :: ('MESH:D014652', 'Disease') :: ['Arterial complications', 'suspicion for further arterial complications']

entities_list: @entity12040 :: ('MESH:D013625', 'Disease') :: ['pulseless extremity']

entities_list: @entity86 :: ('MESH:D019106', 'Disease') :: ['postoperative popliteal artery spasm']

entities_list: @entity2849 :: ('MESH:D017541', 'Disease') :: ['pseudoaneurysm']

answer: @entity2849 :: (MESH:D017541,Disease) :: ['Pseudoaneurysm']


abstract: OBJECTIVES: As our healthcare system moves toward bundling payments, orthopaedic @entity130 surgeons will be increasingly benchmarked on perioperative complications. We therefore sought to determine financial risks under bundled payments by identifying adverse event rates for (1) orthopaedic @entity130 @entity1 compared with general orthopaedic @entity1 and (2) based on anatomic region and (3) to identify @entity1 factors associated with complications. DESIGN: Prospective. SETTING: Multicenter. @entity1 / @entity1 : A total of 146,773 orthopaedic @entity1 (22,361 @entity130 ) from 2005 to 2011 NSQIP data were identified. INTERVENTIONS: Minor and major adverse events, demographics, surgical variables, and @entity1 comorbidities were collected. MAIN OUTCOME MEASUREMENTS: Multivariate regressions determined significant risk factors for the development of complications. RESULTS: The @entity532 rate in the @entity130 group was 11.4% (2554/22,361) versus 4.1% (5137/124,412) in the general orthopaedic group (P = 0.001). When controlling for all variables, @entity130 was a risk factor for developing complications [odds ratio (OR): 1.69, 95% confidence interval (CI): 1.57-1.81]. After controlling for several @entity1 factors, hip and pelvis @entity1 were 4 times more likely to develop any perioperative @entity532 than @entity2045 @entity1 (OR: 3.79, 95% CI: 3.01-4.79, P = 0.01). Lower @entity1746 @entity1 are 3 times more likely to develop any @entity532 versus @entity2045 @entity1 (OR: 2.82, 95% CI: 2.30-3.46, P = 0.01). CONCLUSIONS: Our study is the first to show that orthopaedic @entity130 @entity1 are 2 times more likely than general orthopaedic @entity1 to sustain complications, despite controlling for identical risk factors. There is also an alarming difference in @entity532 rates among anatomic regions. Orthopaedic @entity130 surgeons will face increased financial risk with bundled payments. LEVEL OF EVIDENCE: Prognostic Level II. See Instructions for Authors for a complete description of levels of evidence.

title: Adverse Events in Orthopaedics: Is XXXX More Risky? An Analysis of the NSQIP Data.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS', 'PARTICIPANTS']

entities_list: @entity2045 :: ('MESH:D009207', 'Disease') :: ['upper extremity']

entities_list: @entity532 :: ('MESH:D003925', 'Disease') :: ['complication']

entities_list: @entity1746 :: ('MESH:D020335', 'Disease') :: ['extremity']

answer: @entity130 :: (MESH:D014947,Disease) :: ['Trauma']


abstract: BACKGROUND: Interleukin (IL)-12 is a pro-inflammatory cytokine that mediates T-helper type 1 responses and cytotoxic T-cell activation, contributing to its utility as anti- @entity5 agent. Systemic administration of IL-12 often results in unacceptable @entity137 ; therefore, strategies to direct delivery of IL-12 to @entity5 are under investigation. The objective of this study was to assist the preclinical development of NHS-IL12, an immunocytokine consisting of an antibody, which targets @entity5 regions, linked to IL-12. Specifically this study sought to evaluate the safety, serum pharmacokinetics, anti- @entity5 activity, and immune modulation of NHS-IL12 in @entity235 with naturally occurring @entity5 . METHODOLOGY/PRINCIPAL FINDINGS: A rapid dose-escalation study of NHS-IL12 administered subcutaneously to @entity235 with @entity320 was conducted through the Comparative Oncology Trials Consortium (COTC). Eleven @entity235 were enrolled in four dose-escalation cohorts; thereafter, an additional seven @entity235 were treated at the defined tolerable dose of 0.8 mg/m2. The expanded cohort at this fixed dose (ten @entity235 in total) was accrued for further pharmacokinetics and pharmacodynamics assessment. NHS-IL12 levels, serum cytokine concentrations, and peripheral blood mononuclear cell characterization (post-treatment) and draining lymph node immune profiling, and @entity5 biopsies (pre- and post-treatment) were collected. Adverse events included @entity882 , liver enzymopathies, fever, and @entity1333 . Correlation between interferon (IFN)-y induction, adverse events, and NHS-IL12 exposure (maximum concentration and area under the concentration-time curve) were dose-dependent. Serum @entity14121 levels and intratumoral CD8+ populations increased after treatment. Partial responses, according to Response Evaluation Criteria in @entity5 (RECIST) criteria, were observed in two @entity235 treated with NHS-IL12 0.8 mg/m2 and 1.6 mg/m2. CONCLUSIONS/SIGNIFICANCE: NHS-IL12 was administered safely to @entity235 with @entity320 and both immunologic and clinical activity was observed. This study successfully defined a narrow therapeutic window for systemic delivery of NHS-IL12 via the subcutaneous route. Results will inform the design and implementation of first-in- @entity1 clinical trials of NHS-IL12 in @entity5 @entity1 .

title: Defining the Pharmacodynamic Profile and Therapeutic Index of NHS-IL12 Immunocytokine in @entity235 with XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia']

entities_list: @entity1333 :: ('MESH:D014657', 'Disease') :: ['vasculitis']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Solid Tumors', 'necrotic tumor', 'cancers', 'cancer', 'tumors']

entities_list: @entity320 :: ('MESH:D008545', 'Disease') :: ['melanoma']

answer: @entity320 :: (MESH:D008545,Disease) :: ['Malignant Melanoma']


abstract: BACKGROUND: Interleukin (IL)-12 is a pro-inflammatory cytokine that mediates T-helper type 1 responses and cytotoxic T-cell activation, contributing to its utility as anti- @entity5 agent. Systemic administration of IL-12 often results in unacceptable @entity137 ; therefore, strategies to direct delivery of IL-12 to @entity5 are under investigation. The objective of this study was to assist the preclinical development of NHS-IL12, an immunocytokine consisting of an antibody, which targets @entity5 regions, linked to IL-12. Specifically this study sought to evaluate the safety, serum pharmacokinetics, anti- @entity5 activity, and immune modulation of NHS-IL12 in @entity235 with naturally occurring @entity5 . METHODOLOGY/PRINCIPAL FINDINGS: A rapid dose-escalation study of NHS-IL12 administered subcutaneously to @entity235 with @entity320 was conducted through the Comparative Oncology Trials Consortium (COTC). Eleven @entity235 were enrolled in four dose-escalation cohorts; thereafter, an additional seven @entity235 were treated at the defined tolerable dose of 0.8 mg/m2. The expanded cohort at this fixed dose (ten @entity235 in total) was accrued for further pharmacokinetics and pharmacodynamics assessment. NHS-IL12 levels, serum cytokine concentrations, and peripheral blood mononuclear cell characterization (post-treatment) and draining lymph node immune profiling, and @entity5 biopsies (pre- and post-treatment) were collected. Adverse events included @entity882 , liver enzymopathies, fever, and @entity1333 . Correlation between interferon (IFN)-y induction, adverse events, and NHS-IL12 exposure (maximum concentration and area under the concentration-time curve) were dose-dependent. Serum @entity14121 levels and intratumoral CD8+ populations increased after treatment. Partial responses, according to Response Evaluation Criteria in @entity5 (RECIST) criteria, were observed in two @entity235 treated with NHS-IL12 0.8 mg/m2 and 1.6 mg/m2. CONCLUSIONS/SIGNIFICANCE: NHS-IL12 was administered safely to @entity235 with @entity320 and both immunologic and clinical activity was observed. This study successfully defined a narrow therapeutic window for systemic delivery of NHS-IL12 via the subcutaneous route. Results will inform the design and implementation of first-in- @entity1 clinical trials of NHS-IL12 in @entity5 @entity1 .

title: Defining the Pharmacodynamic Profile and Therapeutic Index of NHS-IL12 Immunocytokine in XXXX with @entity320 .

answer: @entity235 :: (9615,Species) :: ['Dogs']


abstract: The clinical features of @entity9529 ( @entity9529 ) were studied statistically in 106 cases of @entity9529 . The point of the @entity346 at which the @entity1 could best see the targets was detected in some @entity1 . The effects of superior colliculectomy on their visual disturbance and the mechanism will be discussed. The study population comprises 106 @entity1 , 79 males and 27 females, aged from one to 64 (mean 19.4 years). @entity1 with jerky type classified on @entity6459 were found in 53 cases (50%), pendular type in 39 cases (37%), and mixed type in 14 cases (13%). @entity1 with jerky type showed significantly good visual acuity (mean 0.69 +/- 0.31, p less than 0.005). They showed significant abnormalities during pregnancy and delivery (p less than 0.01) and had a neutral point (p less than 0.01). @entity1 with pendular type, on the other hand, showed poor visual acuity (mean 0.26 +/- 0.30) and had significant frequency of family history (p less than 0.05), head @entity400 (p less than 0.01) and strabismus (p less than 0.01). Thirteen cases (12%) had @entity2194 which involved the retina, @entity267 and optic nerve. Visual function was elaborated on such parameters of @entity6459 as perception, peak variation and plateau time. Perception, which means the ability to detect the dim flashes during the appearance of the @entity346 , was manifested by pushing a button when @entity1 could detect flashes presented at random on the screen. At the turning point from the quick phase to the slow phase, the detection was executed most successfully. It is thought that in @entity9529 , a target is usually gazed upon at a point, changing the direction from the quick phase to the slow phase.(ABSTRACT TRUNCATED AT 250 WORDS)

title: [A study of visual function in XXXX --mechanism of visual improvement after stereotactic superior colliculectomy].

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity2194 :: ('MESH:D005128', 'Disease') :: ['ocular diseases']

entities_list: @entity9529 :: ('MESH:D020417', 'Disease') :: ['congenital nystagmus', 'CN']

entities_list: @entity346 :: ('MESH:D009759', 'Disease') :: ['nystagmus']

answer: @entity9529 :: (MESH:D020417,Disease) :: ['congenital nystagmus']


abstract: One-hundred sixty-seven @entity1 with 190 carotid arteries (109 asymptomatic) demonstrating 50-99% stenosis by arteriography (80), duplex scanning, or other noninvasive techniques were followed from 1-84 months (mean 24.2) for evidence of @entity4798 , transient @entity63 attacks, or vertebrobasilar symptoms. Thirty-nine arteries (20.5%) were symptomatic at last follow-up, including 13 (6.8%) producing @entity64 . Twenty-eight sides underwent carotid endarterectomy, 16 for symptomatic lesions at a mean interval of 14.5 months after the initial diagnostic study, with no @entity51 . Twenty-seven @entity1 (16.2%) died, eight from @entity64 (30%), and 12 from cardiac causes (44%). In initially symptomatic sides, the incidence of any subsequent neurologic event (28.7%) or @entity64 /transient @entity63 attack (25%) was significantly greater than in asymptomatic arteries (14.6% and 12%, respectively) (p less than .05). Carotid arteries with greater than 80% stenosis by arteriography and duplex scanning had a 46% incidence of further symptoms and 41.6% @entity64 /transient @entity63 attack rate compared to 19.6% and 15%, respectively, in arteries with less than 80% stenosis (p less than .01). Cumulative life table analysis at 12, 24 and 36 months showed greater than 80% stenosed arteries to have @entity64 /transient @entity63 attack free rates of 69%, 50.5%, and 21.6% compared to 91%, 83.7%, and 76% for arteries with less than 80% stenosis (p less than .05). At a mean follow-up of over two years, nonoperated @entity543 (greater than 50%) carries a 20.5% risk of @entity16 and a 6.8% risk of @entity64 , 61.5% of @entity64 being fatal. Symptomatic @entity543 had a significantly greater incidence of ensuing neurologic events than asymptomatic arteries.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Natural history of nonoperated, significant XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity4798 :: ('MESH:D020520', 'Disease') :: ['brain infarct']

entities_list: @entity64 :: ('MESH:D020521', 'Disease') :: ['strokes', 'ipsilateral strokes', 'stroke']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neurologic symptoms']

entities_list: @entity51 :: ('MESH:D009461', 'Disease') :: ['neurologic deficit']

entities_list: @entity543 :: ('MESH:D016893', 'Disease') :: ['carotid stenosis']

answer: @entity543 :: (MESH:D016893,Disease) :: ['carotid stenosis']


abstract: UNASSIGNED: Purpose To evaluate accuracy and interobserver variability with the use of the Prostate Imaging Reporting and Data System (PI-RADS) version 2.0 for detection of @entity263 at multiparametric magnetic resonance (MR) imaging in a biopsy-na  ve @entity1 population. Materials and Methods This retrospective HIPAA-compliant study was approved by the local ethics committee, and written informed consent was obtained from all @entity1 for use of their imaging and histopathologic data in future research studies. In 101 biopsy-na  ve @entity1 with elevated prostate-specific antigen levels who underwent multiparametric MR imaging of the prostate and subsequent transrectal ultrasonography (US)-MR imaging fusion-guided biopsy, suspicious lesions detected at multiparametric MR imaging were scored by five readers who were blinded to pathologic results by using to the newly revised PI-RADS and the scoring system developed in-house. Interobserver agreement was evaluated by using k statistics, and the correlation of pathologic results with each of the two scoring systems was evaluated by using the Kendall    correlation coefficient. Results Specimens of 162 lesions in 94 @entity1 were sampled by means of transrectal US-MR imaging fusion biopsy. Results for 87 (54%) lesions were positive for @entity263 . Kendall    values with the PI-RADS and the in-house-developed scoring system, respectively, at T2-weighted MR imaging in the peripheral zone were 0.51 and 0.17 and in the transitional zone, 0.45 and -0.11; at diffusion-weighted MR imaging, 0.42 and 0.28; at dynamic contrast material-enhanced MR imaging, 0.23 and 0.24, and overall suspicion scores were 0.42 and 0.49. Median k scores among all possible pairs of readers for PI-RADS and the in-house-developed scoring system, respectively, for T2-weighted MR images in the peripheral zone were 0.47 and 0.15; transitional zone, 0.37 and 0.07; diffusion-weighted MR imaging, 0.41 and 0.57; dynamic contrast-enhanced MR imaging, 0.48 and 0.41; and overall suspicion scores, 0.46 and 0.55. Conclusion Use of the revised PI-RADS provides moderately reproducible MR imaging scores for detection of clinically relevant disease. (  ) RSNA, 2015 Online supplemental material is available for this article.

title: XXXX : Interobserver Agreement and Accuracy with the Revised Prostate Imaging Reporting and Data System at Multiparametric MR Imaging.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer']

answer: @entity263 :: (MESH:D011471,Disease) :: ['Prostate Cancer']


abstract: BACKGROUND: The aims of this study were to describe the basic parameters of adult @entity1 with acute community-onset @entity5746 or campylobacteriosis responsible for more than 90 % of all cases of community-onset @entity294 in the Czech Republic, and, according to the results of this analysis, to update the diagnostic and therapeutic algorithms. MATERIALS AND METHODS: The data were collected retrospectively between January 1, 2011 and December 31, 2013. @entity1 with systemic signs of @entity281 having at least 2 signs of @entity1850 ( @entity1850 ) or with elevated serum @entity1904 levels (more than 0.5 ng/ml) were classified as being at risk for the invasive form of the disease. The remaining @entity1 were classified as having the simple intestinal form of the disease. @entity1 with community-onset post-antibiotic @entity294 were excluded. The data were statistically processed. RESULTS: The following clinical factors were statistically significantly correlated with the high-risk form of the disease: duration of illness of less than 3 days before admission and any of the following (some of them are part of the @entity1850 classification), even after being adjusted for age: body temperature above 38   C, peripheral blood white cell count (WBC) above 12 * 10   /l, neutrophil count above 9 * 10   /l and @entity1851 level above 150 mg/l. The risk form of the disease occurred in 60 cases (18.7 %). The mean WBC was 9.4 * 10   /l (median, 8.4; range, 1.7-89.0). The WBC within the normal range was seen in 194 cases (60.4 %). The mean @entity1851 level was 92.9 mg/l (median, 77.0; range, 1.0-342.0). An elevated @entity1904 level was seen in 21 @entity1 ; the marker was not routinely measured. Positive blood culture results were obtained in 2 @entity1 with @entity5746 ; the examination was not routinely performed. There were 34 @entity1 (10.6 %) with documented immune system dysfunction; the risk form of @entity5746 or campylobacteriosis was seen in only 11 of them (3.4 %). A total of 306 @entity1 (95.3 %) were treated with antibiotics; the mean duration of antibiotic therapy was 8.7 days (median, 7; range, 2-31). CONCLUSIONS: Antibiotic treatment in @entity5746 /campylobacteriosis should not be indicated only due to elevated @entity1851 levels but rather after comprehensive evaluation of the duration of symptoms, individual risk factors and dynamic changes in markers of @entity32 . Blood culture tests should be carried out more frequently.

title: [When should empirical antibiotic therapy be indicated in acute community-onset XXXX of suspected bacterial etiology].

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'persons']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity1904 :: ('MESH:C029100', 'Chemical') :: ['procalcitonin']

entities_list: @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity5746 :: ('MESH:D012480', 'Disease') :: ['salmonellosis']

entities_list: @entity1850 :: ('MESH:D018746', 'Disease') :: ['systemic inflammatory response syndrome', 'SIRS']

answer: @entity294 :: (MESH:D003967,Disease) :: ['diarrhea']


abstract: The present study was designed to examine the question of whether or not there is a natriuretic hormonal substance involved in the renal regulation of @entity1372 balance. For this purpose, procedures for concentration and fractionation of plasma and urine samples and a sensitive bioassay for demonstrating changes in renal @entity1372 excretion were developed. The natriuretic assay utilized @entity35 with mild @entity2010 which were maintained in salt and water balance. Using these approaches a natriuretic humoral substance was demonstrated in plasma and urine from normal @entity1 and @entity742 , and in @entity1 with @entity1368 or essential @entity101 . It seems likely that this substance participates in day to day regulation of @entity1372 balance because it was not detectable in @entity1372 -depleted subjects and it consistently appeared in the @entity1372 -loaded subjects. The hormonal agent may not act immediately and its activity can be apparent for up to 3 hr. Full expression of its activity requires that the assay animals be appropriately volume expanded. This suggests that the increases in @entity1372 excretion mediated by this hormonal substance depend in part on the coparticipation of other physical and perhaps humoral factors. This natriuretic substance appears to be of large molecular weight or carried by a large molecule. The data suggest that it acts, at least in part, to block @entity1372 reabsorption in a more distal portion of the tubule.

title: Natriuretic activity in plasma and urine of salt-loaded @entity1 and XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'man']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity1368 :: ('MESH:D006929', 'Disease') :: ['primary aldosteronism']

entities_list: @entity2010 :: ('MESH:D003919', 'Disease') :: ['diabetes insipidus']

answer: @entity742 :: (9940,Species) :: ['sheep']


abstract: The present study was designed to examine the question of whether or not there is a natriuretic hormonal substance involved in the renal regulation of @entity1372 balance. For this purpose, procedures for concentration and fractionation of plasma and urine samples and a sensitive bioassay for demonstrating changes in renal @entity1372 excretion were developed. The natriuretic assay utilized @entity35 with mild @entity2010 which were maintained in salt and water balance. Using these approaches a natriuretic humoral substance was demonstrated in plasma and urine from normal @entity1 and @entity742 , and in @entity1 with @entity1368 or essential @entity101 . It seems likely that this substance participates in day to day regulation of @entity1372 balance because it was not detectable in @entity1372 -depleted subjects and it consistently appeared in the @entity1372 -loaded subjects. The hormonal agent may not act immediately and its activity can be apparent for up to 3 hr. Full expression of its activity requires that the assay animals be appropriately volume expanded. This suggests that the increases in @entity1372 excretion mediated by this hormonal substance depend in part on the coparticipation of other physical and perhaps humoral factors. This natriuretic substance appears to be of large molecular weight or carried by a large molecule. The data suggest that it acts, at least in part, to block @entity1372 reabsorption in a more distal portion of the tubule.

title: Natriuretic activity in plasma and urine of salt-loaded XXXX and @entity742 .

answer: @entity1 :: (9606,Species) :: ['man']


abstract: Previous studies have demonstrated symptoms and mediator release occurring as long as 11 h after nasal challenge with antigen in selected @entity56 subjects. Pretreatment with systemic @entity230 reduced symptoms and mediators including @entity112 , @entity17703 -esterase activity, and kinins. The aims of the present study were to characterize the cell influx during the late-phase response to antigen challenge and to determine the effect of pretreatment with systemic @entity230 on this response. We examined cytospin slides of nasal washings obtained before and hourly for 11 h after nasal antigen challenge in 10 asymptomatic @entity56 subjects with a history of @entity2023 and 5 normal, nonallergic subjects. Allergic subjects received oral @entity229 (20 mg 3 times a day) or placebo in a random, double-blind crossover manner for 2 days before each of 2 challenges 1 month apart. On placebo days, a mixed cell influx occurred in @entity56 subjects during the late response that was 50-fold greater than the cell influx in the nonallergic control subjects (p less than 0.005). During the first 3 h after antigen challenge, eosinophils (p less than 0.005), but not neutrophils or mononuclear cells, were observed. During the late phase (4 to 11 h), neutrophils, eosinophils, and mononuclear cells were all increased. Oral @entity134 pretreatment blocked the influx of eosinophils (p less than 0.005), but not that of other cells. These data demonstrate an inflammatory cell influx associated with the nasal late-phase response and suggest an important pathogenetic role for the eosinophil.(ABSTRACT TRUNCATED AT 250 WORDS)

title: The influx of inflammatory cells into nasal washings during the late response to antigen challenge. Effect of systemic XXXX pretreatment.

entities_list: @entity2023 :: ('MESH:D006255', 'Disease') :: ['seasonal rhinitis']

entities_list: @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone']

entities_list: @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid']

entities_list: @entity56 :: ('MESH:D004342', 'Disease') :: ['allergic']

entities_list: @entity112 :: ('MESH:D006632', 'Chemical') :: ['histamine']

entities_list: @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids']

answer: @entity134 :: (CHEBI:35341,Chemical) :: ['steroid']


abstract: BACKGROUND: Detection of @entity146 in primary care is a complex issue. Distinctions between ' @entity147 and @entity146 depend on how disorder is conceptualized. Our aim was to explore two different conceptualizations by examining @entity1 ' scores on one-dimensional @entity308 measures and scores on the Four Dimensional Symptom Questionnaire (4DSQ), a measure that uniquely has separate dimensions for general distress and @entity308 . METHODS: This was a cross sectional study of 487 primary care @entity1 attending general clinics in Hampshire, UK. @entity1 completed the 4DSQ, @entity1 Health Questionnaire-9 (PHQ-9), General Health Questionnaire-12 (GHQ-12) and the Hospital Anxiety and @entity308 Scale (HADS) whilst in the waiting room. RESULTS: The 4DSQ classified 26% (126/485) of @entity1 as having heightened distress levels and 8% (38/468) as possible cases of @entity308 . Casesness was consistently higher across the one-dimensional measures (PHQ-9: 16%, GHQ-12: 28%, HADS-D: 13%). Of those @entity1 deemed possible cases by the PHQ-9 (>= 10), the 4DSQ classified 91% (71/78) as having heightened distress and 44% (32/72) as possible cases of @entity308 . LIMITATIONS: The sample was predominately older and white, which may limit generalizability of the findings to more diverse @entity1 groups. There are limits to self-report measures in the assessment of complex diagnostic issues. CONCLUSIONS: Inclusion of a distinct general distress dimension alongside a dimension focusing on specific @entity308 symptomatology lowered the number of primary care @entity1 classified as possible cases of disorder. This view of symptoms may have implications for the targeting of existing treatments, and may be useful in guiding the development of novel self-management interventions.

title: XXXX and @entity146 in primary care attenders: A cross sectional study of the four-dimensional symptom questionnaire (4DSQ).

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'Patient']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['Depression', 'depressive disorder', 'depression']

entities_list: @entity147 :: ('MESH:D005316', 'Disease') :: ["normal' emotional distress"]

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['psychiatric disorder']

answer: @entity147 :: (MESH:D005316,Disease) :: ['Distinguishing between emotional distress']


abstract: BACKGROUND: Detection of @entity146 in primary care is a complex issue. Distinctions between ' @entity147 and @entity146 depend on how disorder is conceptualized. Our aim was to explore two different conceptualizations by examining @entity1 ' scores on one-dimensional @entity308 measures and scores on the Four Dimensional Symptom Questionnaire (4DSQ), a measure that uniquely has separate dimensions for general distress and @entity308 . METHODS: This was a cross sectional study of 487 primary care @entity1 attending general clinics in Hampshire, UK. @entity1 completed the 4DSQ, @entity1 Health Questionnaire-9 (PHQ-9), General Health Questionnaire-12 (GHQ-12) and the Hospital Anxiety and @entity308 Scale (HADS) whilst in the waiting room. RESULTS: The 4DSQ classified 26% (126/485) of @entity1 as having heightened distress levels and 8% (38/468) as possible cases of @entity308 . Casesness was consistently higher across the one-dimensional measures (PHQ-9: 16%, GHQ-12: 28%, HADS-D: 13%). Of those @entity1 deemed possible cases by the PHQ-9 (>= 10), the 4DSQ classified 91% (71/78) as having heightened distress and 44% (32/72) as possible cases of @entity308 . LIMITATIONS: The sample was predominately older and white, which may limit generalizability of the findings to more diverse @entity1 groups. There are limits to self-report measures in the assessment of complex diagnostic issues. CONCLUSIONS: Inclusion of a distinct general distress dimension alongside a dimension focusing on specific @entity308 symptomatology lowered the number of primary care @entity1 classified as possible cases of disorder. This view of symptoms may have implications for the targeting of existing treatments, and may be useful in guiding the development of novel self-management interventions.

title: @entity147 and XXXX in primary care attenders: A cross sectional study of the four-dimensional symptom questionnaire (4DSQ).

answer: @entity146 :: (MESH:D001523,Disease) :: ['psychiatric disorder']


abstract: BACKGROUND: The aim of this study was to investigate the clinical efficacy of B-mode ultrasound-guided retroperitoneal and abdominal catheter treatment of severe acute @entity788 . METHODS: A retrospective analysis was performed, regarding 68 @entity1 diagnosed with severe acute @entity788 in our hospital from May 2012 to May 2014. @entity1 were divided into an observation group (N.=38) and a control group (N.=30). @entity1 in the control group received conventional drug therapy and were given CT-guided catheter or surgical treatment when necessary. The observation group received conventional drug therapy + B-mode ultrasound-guided retroperitoneal and abdominal catheter drainage and lavage. The clinical efficacy and complication rate differences of the two groups of @entity1 were compared and analyzed. RESULTS: The total efficacy rates in the observation group were significantly higher than in the control group (P<0.05). The serum @entity460 levels of the observation group were obviously higher than that of the control group while their CRP levels and APACHE II scores were significantly lower (P<0.05). Complications were significantly lower in the observation group than in the control group (P<0.05). CONCLUSIONS: B-mode ultrasound-guided biopsy for retroperitoneal and abdominal subcutaneous catheter drainage and lavage treatment of severe acute @entity788 may improve the clinical effect and reduce complications.

title: Clinical study of B-mode ultrasound-guided retroperitoneal and abdominal catheter treatment of severe acute XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'Patients']

entities_list: @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatitis']

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']

answer: @entity788 :: (MESH:D010190,Disease) :: ['pancreatitis']


abstract: OBJECTIVES: To evaluate changes in annual blood transfusion requirements and complications after splenectomy in @entity1 with @entity2395 . METHODS: Forty post-splenectomy b-thalassemic @entity1 aged 8-33  y, receiving regular blood transfusions and chelation therapy were included and non transfusion dependant @entity1 were excluded from this retrospective cross-sectional study. Details about their surgery, transfusion requirements, and platelet levels were recorded on a standard proforma. All @entity1 underwent a B-mode and color-coded duplex sonography of the hepatoportal system during the study period. RESULTS: The average ferritin level in the year prior to the study was 4432 mcg/L (range 480-12,200 mcg/L). The annual blood transfusion requirement in the first year and 5  y post splenectomy [mean        SD (138.41        90.38  ml/kg/y); (116        41.44  ml/kg/y)] were significantly different from requirements before splenectomy [(mean        SD) 294.85        226  ml/kg/y; p value <0.001]. There was a significant rise in platelet counts within 24  h post splenectomy with a mean rise of 4,51,000/mm(3) (p value   <   0.001). During the follow up period, infections were noted in 50  % of @entity1 , with @entity311 (18.75  %) being the most common. Doppler study of the portal system in one case showed @entity715 . CONCLUSIONS: A significant sustained fall in annual blood transfusion requirement and a rise in platelet counts occurred post-splenectomy. Increase in annual blood transfusion requirement should be investigated to find the cause.

title: Post Splenectomy Outcome in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['portal vein thrombosis']

entities_list: @entity2395 :: ('MESH:D013789', 'Disease') :: ['b-thalassemia']

answer: @entity2395 :: (MESH:D013789,Disease) :: ['b-Thalassemia']


abstract: UNASSIGNED: @entity25306 , an alkaloid extracted from medicinal plants of the genus Sophora, has a wide range of pharmacological effects. Previous studies have revealed that @entity25306 can inhibit proliferation and metastasis of @entity5 cells through reducing @entity1476 ( @entity1476 ) mRNA expression. However, the expression of @entity1476 in @entity43 is significantly higher than that in normal ovaries. Furthermore, the expression of microRNA  -29b ( @entity15702 ) in @entity43 is significantly lower than that in normal ovaries. Therefore, @entity1476 and @entity15702 are @entity5 suppressor factors involved in @entity43 . To evaluate the anti- @entity5 effects of @entity25306 the @entity1 @entity43 cell line was treated with @entity25306 at the concentrations of 0, 0.5, 1 and 2  mg/ml. Assessment of the proliferation and apoptosis of @entity1 cells showed that @entity25306 had an inhibitory effect on @entity43 cells. Furthermore, @entity25306 decreased the protein levels of @entity1476 and increased the expression levels of @entity15702 in @entity1 cells. Through transfection of @entity15702 precursor into @entity1 cells, it was demonstrated that @entity15702 regulated @entity1476 expression in @entity1 cells. In addition, anti  - @entity15702 antibodies were used to verify that the apoptotic effect of @entity25306 was due to upregulating @entity15702 and downregulating @entity1476 expression. These results showed that @entity25306 suppresses the proliferation and facilitates apoptosis of @entity1 @entity43 cells through upregulating @entity15702 and downregulating @entity1476 expression.

title: XXXX suppresses proliferation and facilitates apoptosis of @entity1 @entity43 cells through upregulating microRNA  -29b and downregulating @entity1476 expression.

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian carcinoma', 'ovarian cancer', 'ovary cancer']

entities_list: @entity1476 :: ('4313', 'Gene') :: ['MMP  -2', 'matrix metalloproteinase  -2']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer']

entities_list: @entity25306 :: ('MESH:C037573', 'Chemical') :: ['Oxymatrine', 'oxymatrine']

answer: @entity25306 :: (MESH:C037573,Chemical) :: ['Oxymatrine']


abstract: UNASSIGNED: @entity25306 , an alkaloid extracted from medicinal plants of the genus Sophora, has a wide range of pharmacological effects. Previous studies have revealed that @entity25306 can inhibit proliferation and metastasis of @entity5 cells through reducing @entity1476 ( @entity1476 ) mRNA expression. However, the expression of @entity1476 in @entity43 is significantly higher than that in normal ovaries. Furthermore, the expression of microRNA  -29b ( @entity15702 ) in @entity43 is significantly lower than that in normal ovaries. Therefore, @entity1476 and @entity15702 are @entity5 suppressor factors involved in @entity43 . To evaluate the anti- @entity5 effects of @entity25306 the @entity1 @entity43 cell line was treated with @entity25306 at the concentrations of 0, 0.5, 1 and 2  mg/ml. Assessment of the proliferation and apoptosis of @entity1 cells showed that @entity25306 had an inhibitory effect on @entity43 cells. Furthermore, @entity25306 decreased the protein levels of @entity1476 and increased the expression levels of @entity15702 in @entity1 cells. Through transfection of @entity15702 precursor into @entity1 cells, it was demonstrated that @entity15702 regulated @entity1476 expression in @entity1 cells. In addition, anti  - @entity15702 antibodies were used to verify that the apoptotic effect of @entity25306 was due to upregulating @entity15702 and downregulating @entity1476 expression. These results showed that @entity25306 suppresses the proliferation and facilitates apoptosis of @entity1 @entity43 cells through upregulating @entity15702 and downregulating @entity1476 expression.

title: @entity25306 suppresses proliferation and facilitates apoptosis of @entity1 @entity43 cells through upregulating microRNA  -29b and downregulating XXXX expression.

answer: @entity1476 :: (4313,Gene) :: ['matrix metalloproteinase  -2']


abstract: UNASSIGNED: @entity25306 , an alkaloid extracted from medicinal plants of the genus Sophora, has a wide range of pharmacological effects. Previous studies have revealed that @entity25306 can inhibit proliferation and metastasis of @entity5 cells through reducing @entity1476 ( @entity1476 ) mRNA expression. However, the expression of @entity1476 in @entity43 is significantly higher than that in normal ovaries. Furthermore, the expression of microRNA  -29b ( @entity15702 ) in @entity43 is significantly lower than that in normal ovaries. Therefore, @entity1476 and @entity15702 are @entity5 suppressor factors involved in @entity43 . To evaluate the anti- @entity5 effects of @entity25306 the @entity1 @entity43 cell line was treated with @entity25306 at the concentrations of 0, 0.5, 1 and 2  mg/ml. Assessment of the proliferation and apoptosis of @entity1 cells showed that @entity25306 had an inhibitory effect on @entity43 cells. Furthermore, @entity25306 decreased the protein levels of @entity1476 and increased the expression levels of @entity15702 in @entity1 cells. Through transfection of @entity15702 precursor into @entity1 cells, it was demonstrated that @entity15702 regulated @entity1476 expression in @entity1 cells. In addition, anti  - @entity15702 antibodies were used to verify that the apoptotic effect of @entity25306 was due to upregulating @entity15702 and downregulating @entity1476 expression. These results showed that @entity25306 suppresses the proliferation and facilitates apoptosis of @entity1 @entity43 cells through upregulating @entity15702 and downregulating @entity1476 expression.

title: @entity25306 suppresses proliferation and facilitates apoptosis of @entity1 XXXX cells through upregulating microRNA  -29b and downregulating @entity1476 expression.

answer: @entity43 :: (MESH:D010051,Disease) :: ['ovarian cancer']


abstract: UNASSIGNED: @entity25306 , an alkaloid extracted from medicinal plants of the genus Sophora, has a wide range of pharmacological effects. Previous studies have revealed that @entity25306 can inhibit proliferation and metastasis of @entity5 cells through reducing @entity1476 ( @entity1476 ) mRNA expression. However, the expression of @entity1476 in @entity43 is significantly higher than that in normal ovaries. Furthermore, the expression of microRNA  -29b ( @entity15702 ) in @entity43 is significantly lower than that in normal ovaries. Therefore, @entity1476 and @entity15702 are @entity5 suppressor factors involved in @entity43 . To evaluate the anti- @entity5 effects of @entity25306 the @entity1 @entity43 cell line was treated with @entity25306 at the concentrations of 0, 0.5, 1 and 2  mg/ml. Assessment of the proliferation and apoptosis of @entity1 cells showed that @entity25306 had an inhibitory effect on @entity43 cells. Furthermore, @entity25306 decreased the protein levels of @entity1476 and increased the expression levels of @entity15702 in @entity1 cells. Through transfection of @entity15702 precursor into @entity1 cells, it was demonstrated that @entity15702 regulated @entity1476 expression in @entity1 cells. In addition, anti  - @entity15702 antibodies were used to verify that the apoptotic effect of @entity25306 was due to upregulating @entity15702 and downregulating @entity1476 expression. These results showed that @entity25306 suppresses the proliferation and facilitates apoptosis of @entity1 @entity43 cells through upregulating @entity15702 and downregulating @entity1476 expression.

title: @entity25306 suppresses proliferation and facilitates apoptosis of XXXX @entity43 cells through upregulating microRNA  -29b and downregulating @entity1476 expression.

answer: @entity1 :: (9606,Species) :: ['human']


abstract: BACKGROUND: @entity32 is considered one of the major causes of protein-energy wasting in @entity22 ( @entity22 ) @entity1 . It is unclear whether dietary interventions can impact nutritional status and quality of life in @entity22 @entity1 with elevated @entity1851 ( @entity1851 ) levels. Therefore, we examined the hypothesis that supervised intra-dialysis protein supplementation in @entity22 @entity1 with elevated plasma @entity1851 will improve protein stores and quality of life. METHODS: A 24  week, two phase, longitudinal, single center, open labeled study of 50 @entity22 @entity1 with plasma @entity29726  mg/L was conducted. During the 12-week observation phase dietary advice was provided to increase protein intake to 1.2  g/kg/day. In the 12-week treatment phase 45  g of liquid protein supplement was provided at each dialysis treatment. Protein @entity1568 appearance (PNA), mid-arm muscle circumference (MAMC), serum albumin, body mass index (BMI) and quality of life (assessed by Short Form-12 questionnaire) were measured at baseline, 12 and 24  weeks. RESULTS: Median plasma @entity1851 at baseline was 16.0 (IQR 7.7 to 25.1) mg/L. The mean MAMC was 26.5        3.9  cm, BMI 29.2        6.9  kg/m(2) and plasma albumin 3.8        0.3  g/dl. During the intervention period, mean PNA increased by 0.13  g/kg/d (p   =   0.01) under a mixed effects model. However, there were no clinically or statistically significant effects on MAMC (p   =   0.87), plasma albumin (p   =   0.70), BMI (p   =   0.09), physical (p   =   0.32) or mental (p   =   0.96) composite scores. CONCLUSIONS: In @entity22 @entity1 with elevated plasma @entity1851 but otherwise mostly normal nutritional parameters, intra-dialytic oral protein supplement was effective in increasing protein intake but did not provide a detectable impact on nutritional status or quality of life.

title: Supervised oral protein supplementation during dialysis in @entity1 with elevated XXXX levels: a two phase, longitudinal, single center, open labeled study.

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['Inflammation']

entities_list: @entity1568 :: ('MESH:D009584', 'Chemical') :: ['nitrogen']

entities_list: @entity22 :: ('MESH:D007319', 'Disease') :: ['maintenance hemodialysis', 'MHD']

entities_list: @entity1851 :: ('1401', 'Gene') :: ['C-reactive protein', 'CRP']

answer: @entity1851 :: (1401,Gene) :: ['C-reactive protein']


abstract: BACKGROUND: @entity32 is considered one of the major causes of protein-energy wasting in @entity22 ( @entity22 ) @entity1 . It is unclear whether dietary interventions can impact nutritional status and quality of life in @entity22 @entity1 with elevated @entity1851 ( @entity1851 ) levels. Therefore, we examined the hypothesis that supervised intra-dialysis protein supplementation in @entity22 @entity1 with elevated plasma @entity1851 will improve protein stores and quality of life. METHODS: A 24  week, two phase, longitudinal, single center, open labeled study of 50 @entity22 @entity1 with plasma @entity29726  mg/L was conducted. During the 12-week observation phase dietary advice was provided to increase protein intake to 1.2  g/kg/day. In the 12-week treatment phase 45  g of liquid protein supplement was provided at each dialysis treatment. Protein @entity1568 appearance (PNA), mid-arm muscle circumference (MAMC), serum albumin, body mass index (BMI) and quality of life (assessed by Short Form-12 questionnaire) were measured at baseline, 12 and 24  weeks. RESULTS: Median plasma @entity1851 at baseline was 16.0 (IQR 7.7 to 25.1) mg/L. The mean MAMC was 26.5        3.9  cm, BMI 29.2        6.9  kg/m(2) and plasma albumin 3.8        0.3  g/dl. During the intervention period, mean PNA increased by 0.13  g/kg/d (p   =   0.01) under a mixed effects model. However, there were no clinically or statistically significant effects on MAMC (p   =   0.87), plasma albumin (p   =   0.70), BMI (p   =   0.09), physical (p   =   0.32) or mental (p   =   0.96) composite scores. CONCLUSIONS: In @entity22 @entity1 with elevated plasma @entity1851 but otherwise mostly normal nutritional parameters, intra-dialytic oral protein supplement was effective in increasing protein intake but did not provide a detectable impact on nutritional status or quality of life.

title: Supervised oral protein supplementation during dialysis in XXXX with elevated @entity1851 levels: a two phase, longitudinal, single center, open labeled study.

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: Effects of @entity28 and age on @entity920 , @entity68 , @entity219 , @entity1372 , @entity972 , and protein were compared in liver, kidney, brain, and muscle of @entity28 (fa/fa) and nonobese (non-fa/fa) male Zucker @entity35 . Blood plasma cerulopasmin, @entity920 , @entity219 , @entity1372 , and @entity972 were also determined. Mean brain weight of fa/fa @entity35 was less than that of non-fa/fa @entity35 at 12 weeks of age; mean brain protein concentration was greater in fa/fa than in non-fa/fa at 5 and 12 weeks of age. At 18-19 days of age, mean @entity1372 concentration (mg/g protein) in liver of fa/fa was less than that of non-fa/fa. At 5 weeks of age, mean @entity920 concentration (microgram/g protein) in kidney was greater in fa/fa. Mean total @entity920 , @entity68 , @entity219 , @entity1372 , and @entity972 in liver and kidney were greater in fa/fa than in non-fa/fa at 5 weeks because of the larger livers and kidneys of fa/fa. Mean concentrations of @entity920 , @entity219 , @entity1372 , and @entity972 per gram of brain protein were slightly (6-10%) less in fa/fa than in non-fa/fa at 5 weeks. By 12 weeks, mean concentrations of @entity920 in liver, kidney, (tibialis) muscle, and blood plasma, ceruloplasmin in blood plasma, @entity219 in liver and muscle, @entity68 in muscle, and @entity1372 in liver were greater in fa/fa than in non-fa/fa. However, total amount of each mineral in muscle at 12 weeks was less in fa/fa than in non-fa/fa because of the smaller mean muscle weight of fa/fa. Mean concentrations of @entity920 and @entity219 in brain and of @entity68 in liver and brain were less in fa/fa than in non-fa/fa at 12 weeks. The major age-related changes in fa/fa that were not observed in non-fa/fa were large increases in liver and kidney @entity920 between 5 and 12 weeks of age. It seems that the abnormal mineral metabolism is a consequence of the @entity28 , but the mechanisms are not identified.

title: Developmental changes of selected minerals in Zucker XXXX .

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['obese', 'obesity']

entities_list: @entity972 :: ('MESH:D011188', 'Chemical') :: ['potassium']

answer: @entity35 :: (10116,Species) :: ['rats']


abstract: PURPOSE: This case report describes the treatment of a rare @entity281 caused by @entity23232 with @entity7048 and @entity1215 . SUMMARY: A 48-year-old @entity1 with significant comorbidities was admitted to our institution with complaints of malaise, @entity1353 , and vague persistent @entity158 . He was diagnosed with @entity23232 @entity884 and was treated with @entity7048 continuous infusion for 10 days without resolution of @entity2259 . As surgical intervention was deemed inappropriate, @entity1215 was added to the treatment regimen for its antibiofilm activity. After @entity1215 initiation, resolution of @entity2259 was rapidly achieved. Subsequent blood cultures remained negative, and the @entity1 was discharged home in stable condition to complete six weeks of i.v. @entity7048 and @entity1215 therapy. The @entity1 continued treatment, as documented by the infusion center, weekly for five weeks. The @entity1 was rehospitalized during his sixth week of treatment due to impending @entity1576 , whereupon he was intubated and admitted to the intensive care unit. The @entity1 's cardiac status gradually worsened over the following days, and he ultimately died. Blood cultures from days 1 and 2 of hospitalization revealed no bacterial growth at five days. CONCLUSION: @entity7048 and @entity1215 therapy in a hospitalized @entity1 with @entity2259 and @entity886 caused by @entity23232 resulted in rapid eradication of the @entity2259 . After more than five weeks of @entity7048 - @entity1215 treatment, the @entity1 was rehospitalized with worsening cardiac function and died. Blood cultures during the second admission were negative.

title: @entity23232 XXXX and @entity884 treated with @entity7048 and @entity1215 .

entities_list: @entity7048 :: ('MESH:D002437', 'Chemical') :: ['cefazolin', 'Cefazolin']

entities_list: @entity1353 :: ('MESH:D004417', 'Disease') :: ['shortness of breath']

entities_list: @entity886 :: ('MESH:C563178', 'Disease') :: ['aortic valve endocarditis']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity1576 :: ('MESH:D012131', 'Disease') :: ['respiratory failure']

entities_list: @entity1215 :: ('MESH:D012293', 'Chemical') :: ['rifampin']

entities_list: @entity23232 :: ('28035', 'Species') :: ['Staphylococcus lugdunensis', 'S. lugdunensis']

entities_list: @entity2259 :: ('MESH:D016470', 'Disease') :: ['bacteremia']

entities_list: @entity884 :: ('MESH:D004696', 'Disease') :: ['infective endocarditis']

answer: @entity2259 :: (MESH:D016470,Disease) :: ['bacteremia']


abstract: PURPOSE: This case report describes the treatment of a rare @entity281 caused by @entity23232 with @entity7048 and @entity1215 . SUMMARY: A 48-year-old @entity1 with significant comorbidities was admitted to our institution with complaints of malaise, @entity1353 , and vague persistent @entity158 . He was diagnosed with @entity23232 @entity884 and was treated with @entity7048 continuous infusion for 10 days without resolution of @entity2259 . As surgical intervention was deemed inappropriate, @entity1215 was added to the treatment regimen for its antibiofilm activity. After @entity1215 initiation, resolution of @entity2259 was rapidly achieved. Subsequent blood cultures remained negative, and the @entity1 was discharged home in stable condition to complete six weeks of i.v. @entity7048 and @entity1215 therapy. The @entity1 continued treatment, as documented by the infusion center, weekly for five weeks. The @entity1 was rehospitalized during his sixth week of treatment due to impending @entity1576 , whereupon he was intubated and admitted to the intensive care unit. The @entity1 's cardiac status gradually worsened over the following days, and he ultimately died. Blood cultures from days 1 and 2 of hospitalization revealed no bacterial growth at five days. CONCLUSION: @entity7048 and @entity1215 therapy in a hospitalized @entity1 with @entity2259 and @entity886 caused by @entity23232 resulted in rapid eradication of the @entity2259 . After more than five weeks of @entity7048 - @entity1215 treatment, the @entity1 was rehospitalized with worsening cardiac function and died. Blood cultures during the second admission were negative.

title: XXXX @entity2259 and @entity884 treated with @entity7048 and @entity1215 .

answer: @entity23232 :: (28035,Species) :: ['Staphylococcus lugdunensis']


abstract: PURPOSE: This case report describes the treatment of a rare @entity281 caused by @entity23232 with @entity7048 and @entity1215 . SUMMARY: A 48-year-old @entity1 with significant comorbidities was admitted to our institution with complaints of malaise, @entity1353 , and vague persistent @entity158 . He was diagnosed with @entity23232 @entity884 and was treated with @entity7048 continuous infusion for 10 days without resolution of @entity2259 . As surgical intervention was deemed inappropriate, @entity1215 was added to the treatment regimen for its antibiofilm activity. After @entity1215 initiation, resolution of @entity2259 was rapidly achieved. Subsequent blood cultures remained negative, and the @entity1 was discharged home in stable condition to complete six weeks of i.v. @entity7048 and @entity1215 therapy. The @entity1 continued treatment, as documented by the infusion center, weekly for five weeks. The @entity1 was rehospitalized during his sixth week of treatment due to impending @entity1576 , whereupon he was intubated and admitted to the intensive care unit. The @entity1 's cardiac status gradually worsened over the following days, and he ultimately died. Blood cultures from days 1 and 2 of hospitalization revealed no bacterial growth at five days. CONCLUSION: @entity7048 and @entity1215 therapy in a hospitalized @entity1 with @entity2259 and @entity886 caused by @entity23232 resulted in rapid eradication of the @entity2259 . After more than five weeks of @entity7048 - @entity1215 treatment, the @entity1 was rehospitalized with worsening cardiac function and died. Blood cultures during the second admission were negative.

title: @entity23232 @entity2259 and @entity884 treated with XXXX and @entity1215 .

answer: @entity7048 :: (MESH:D002437,Chemical) :: ['cefazolin']


abstract: PURPOSE: This case report describes the treatment of a rare @entity281 caused by @entity23232 with @entity7048 and @entity1215 . SUMMARY: A 48-year-old @entity1 with significant comorbidities was admitted to our institution with complaints of malaise, @entity1353 , and vague persistent @entity158 . He was diagnosed with @entity23232 @entity884 and was treated with @entity7048 continuous infusion for 10 days without resolution of @entity2259 . As surgical intervention was deemed inappropriate, @entity1215 was added to the treatment regimen for its antibiofilm activity. After @entity1215 initiation, resolution of @entity2259 was rapidly achieved. Subsequent blood cultures remained negative, and the @entity1 was discharged home in stable condition to complete six weeks of i.v. @entity7048 and @entity1215 therapy. The @entity1 continued treatment, as documented by the infusion center, weekly for five weeks. The @entity1 was rehospitalized during his sixth week of treatment due to impending @entity1576 , whereupon he was intubated and admitted to the intensive care unit. The @entity1 's cardiac status gradually worsened over the following days, and he ultimately died. Blood cultures from days 1 and 2 of hospitalization revealed no bacterial growth at five days. CONCLUSION: @entity7048 and @entity1215 therapy in a hospitalized @entity1 with @entity2259 and @entity886 caused by @entity23232 resulted in rapid eradication of the @entity2259 . After more than five weeks of @entity7048 - @entity1215 treatment, the @entity1 was rehospitalized with worsening cardiac function and died. Blood cultures during the second admission were negative.

title: @entity23232 @entity2259 and XXXX treated with @entity7048 and @entity1215 .

answer: @entity884 :: (MESH:D004696,Disease) :: ['endocarditis']


abstract: PURPOSE: This case report describes the treatment of a rare @entity281 caused by @entity23232 with @entity7048 and @entity1215 . SUMMARY: A 48-year-old @entity1 with significant comorbidities was admitted to our institution with complaints of malaise, @entity1353 , and vague persistent @entity158 . He was diagnosed with @entity23232 @entity884 and was treated with @entity7048 continuous infusion for 10 days without resolution of @entity2259 . As surgical intervention was deemed inappropriate, @entity1215 was added to the treatment regimen for its antibiofilm activity. After @entity1215 initiation, resolution of @entity2259 was rapidly achieved. Subsequent blood cultures remained negative, and the @entity1 was discharged home in stable condition to complete six weeks of i.v. @entity7048 and @entity1215 therapy. The @entity1 continued treatment, as documented by the infusion center, weekly for five weeks. The @entity1 was rehospitalized during his sixth week of treatment due to impending @entity1576 , whereupon he was intubated and admitted to the intensive care unit. The @entity1 's cardiac status gradually worsened over the following days, and he ultimately died. Blood cultures from days 1 and 2 of hospitalization revealed no bacterial growth at five days. CONCLUSION: @entity7048 and @entity1215 therapy in a hospitalized @entity1 with @entity2259 and @entity886 caused by @entity23232 resulted in rapid eradication of the @entity2259 . After more than five weeks of @entity7048 - @entity1215 treatment, the @entity1 was rehospitalized with worsening cardiac function and died. Blood cultures during the second admission were negative.

title: @entity23232 @entity2259 and @entity884 treated with @entity7048 and XXXX .

answer: @entity1215 :: (MESH:D012293,Chemical) :: ['rifampin']


abstract: BACKGROUND: To establish the effect of the task-based mirror therapy (TBMT) on the upper limb recovery in @entity64 . METHODS: A pilot, randomized, controlled, assessor-blinded trial was conducted in a rehabilitation institute. A convenience sample of 33 poststroke (mean duration, 12.5  months) hemiparetic subjects was randomized into 2 groups (experimental, 17; control, 16). The subjects were allocated to receive either TBMT or standard motor rehabilitation-40 sessions (5/week) for a period of 8  weeks. The TBMT group received movements using various goal-directed tasks and a mirror box. The movements were performed by the less-affected side superimposed on the affected side. The main outcome measures were Brunnstrom recovery stage ( @entity4375 ) and Fugl-Meyer assessment (FMA)-FMA of upper extremity (FMA-UE), including upper arm (FMA-UA) and wrist-hand (FMA-WH). RESULTS: The TBMT group exhibited highly significant improvement on mean scores of FMA-WH (P  <  .001) and FMA-UE (P  <  .001) at postassessment in comparison to the control group. Furthermore, there was a 12% increase in the number of subjects at @entity4375 stage 5 (out of synergy movement) in the experimental group as compared to a 0% rise at the same stage in the control group. CONCLUSIONS: This pilot trial confirmed the role of TBMT in improving the wrist-hand motor recovery in @entity1269 . MT using tasks may be used as an adjunct in @entity64 rehabilitation.

title: Task-Based Mirror Therapy Augmenting Motor Recovery in XXXX : A Randomized Controlled Trial.

entities_list: @entity1269 :: ('MESH:D010291', 'Disease') :: ['poststroke hemiparesis']

answer: @entity1269 :: (MESH:D010291,Disease) :: ['Poststroke Hemiparesis']


abstract: UNASSIGNED: The pathogenic amoeba @entity2330 is one of the causative agents of health hazards in tropical countries. It causes @entity16126 , @entity1960 and @entity5572 in @entity1 . @entity68 is one of the essential nutritional resources for survival and @entity281 caused by the amoeba. The parasite has developed multiple ways to import, sequester and utilize @entity68 from various @entity68 -binding proteins from its host. In spite of its central role in pathogenesis, the mechanism of @entity68 uptake by the parasite is largely unknown. Here, we carried out a systematic study to understand the role of some of the amoebic homologues of @entity1 endocytic Rab GTPases ( @entity4814 and @entity38148 , @entity27341 and @entity21219 ) in intracellular transport of @entity1 holo- @entity69 by the parasite. Flow cytometry and quantitative microscopic image analysis revealed that @entity4814 and @entity27341 are required for the biogenesis of amoebic giant endocytic vacuoles (GEVs) and regulate the early phase of intracellular trafficking of @entity69 . @entity21219 is involved in the late phase, leading to the degradation of @entity69 in the amoebic lysosome-like compartments. Using time-lapse fluorescence imaging in fixed trophozoites, we determined the kinetics of the vesicular transport of @entity69 through @entity4814 -, @entity27341 - and @entity21219 -positive compartments. The involvement of @entity27341 in the early phase of endocytosis by the parasite marks a significant divergence from its host in terms of spatiotemporal regulation by the Rab GTPases.

title: Insights into endosomal maturation of @entity1 holo- @entity69 in the enteric parasite @entity2330 : essential roles of @entity27341 and XXXX in biogenesis of giant early endocytic vacuoles.

entities_list: @entity5572 :: ('MESH:D008100', 'Disease') :: ['liver abscesses']

entities_list: @entity1 :: ('9606', 'Species') :: ['mammalian', 'human']

entities_list: @entity16126 :: ('MESH:D004404', 'Disease') :: ['amoebic dysentery']

entities_list: @entity2330 :: ('5759', 'Species') :: ['Entamoeba histolytica']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['chronic infection']

answer: @entity4814 :: (5868,Gene) :: ['Rab5']


abstract: UNASSIGNED: The pathogenic amoeba @entity2330 is one of the causative agents of health hazards in tropical countries. It causes @entity16126 , @entity1960 and @entity5572 in @entity1 . @entity68 is one of the essential nutritional resources for survival and @entity281 caused by the amoeba. The parasite has developed multiple ways to import, sequester and utilize @entity68 from various @entity68 -binding proteins from its host. In spite of its central role in pathogenesis, the mechanism of @entity68 uptake by the parasite is largely unknown. Here, we carried out a systematic study to understand the role of some of the amoebic homologues of @entity1 endocytic Rab GTPases ( @entity4814 and @entity38148 , @entity27341 and @entity21219 ) in intracellular transport of @entity1 holo- @entity69 by the parasite. Flow cytometry and quantitative microscopic image analysis revealed that @entity4814 and @entity27341 are required for the biogenesis of amoebic giant endocytic vacuoles (GEVs) and regulate the early phase of intracellular trafficking of @entity69 . @entity21219 is involved in the late phase, leading to the degradation of @entity69 in the amoebic lysosome-like compartments. Using time-lapse fluorescence imaging in fixed trophozoites, we determined the kinetics of the vesicular transport of @entity69 through @entity4814 -, @entity27341 - and @entity21219 -positive compartments. The involvement of @entity27341 in the early phase of endocytosis by the parasite marks a significant divergence from its host in terms of spatiotemporal regulation by the Rab GTPases.

title: Insights into endosomal maturation of @entity1 holo- XXXX in the enteric parasite @entity2330 : essential roles of @entity27341 and @entity4814 in biogenesis of giant early endocytic vacuoles.

answer: @entity69 :: (7018,Gene) :: ['transferrin']


abstract: UNASSIGNED: The pathogenic amoeba @entity2330 is one of the causative agents of health hazards in tropical countries. It causes @entity16126 , @entity1960 and @entity5572 in @entity1 . @entity68 is one of the essential nutritional resources for survival and @entity281 caused by the amoeba. The parasite has developed multiple ways to import, sequester and utilize @entity68 from various @entity68 -binding proteins from its host. In spite of its central role in pathogenesis, the mechanism of @entity68 uptake by the parasite is largely unknown. Here, we carried out a systematic study to understand the role of some of the amoebic homologues of @entity1 endocytic Rab GTPases ( @entity4814 and @entity38148 , @entity27341 and @entity21219 ) in intracellular transport of @entity1 holo- @entity69 by the parasite. Flow cytometry and quantitative microscopic image analysis revealed that @entity4814 and @entity27341 are required for the biogenesis of amoebic giant endocytic vacuoles (GEVs) and regulate the early phase of intracellular trafficking of @entity69 . @entity21219 is involved in the late phase, leading to the degradation of @entity69 in the amoebic lysosome-like compartments. Using time-lapse fluorescence imaging in fixed trophozoites, we determined the kinetics of the vesicular transport of @entity69 through @entity4814 -, @entity27341 - and @entity21219 -positive compartments. The involvement of @entity27341 in the early phase of endocytosis by the parasite marks a significant divergence from its host in terms of spatiotemporal regulation by the Rab GTPases.

title: Insights into endosomal maturation of @entity1 holo- @entity69 in the enteric parasite @entity2330 : essential roles of XXXX and @entity4814 in biogenesis of giant early endocytic vacuoles.

answer: @entity27341 :: (7879,Gene) :: ['Rab7A']


abstract: UNASSIGNED: The pathogenic amoeba @entity2330 is one of the causative agents of health hazards in tropical countries. It causes @entity16126 , @entity1960 and @entity5572 in @entity1 . @entity68 is one of the essential nutritional resources for survival and @entity281 caused by the amoeba. The parasite has developed multiple ways to import, sequester and utilize @entity68 from various @entity68 -binding proteins from its host. In spite of its central role in pathogenesis, the mechanism of @entity68 uptake by the parasite is largely unknown. Here, we carried out a systematic study to understand the role of some of the amoebic homologues of @entity1 endocytic Rab GTPases ( @entity4814 and @entity38148 , @entity27341 and @entity21219 ) in intracellular transport of @entity1 holo- @entity69 by the parasite. Flow cytometry and quantitative microscopic image analysis revealed that @entity4814 and @entity27341 are required for the biogenesis of amoebic giant endocytic vacuoles (GEVs) and regulate the early phase of intracellular trafficking of @entity69 . @entity21219 is involved in the late phase, leading to the degradation of @entity69 in the amoebic lysosome-like compartments. Using time-lapse fluorescence imaging in fixed trophozoites, we determined the kinetics of the vesicular transport of @entity69 through @entity4814 -, @entity27341 - and @entity21219 -positive compartments. The involvement of @entity27341 in the early phase of endocytosis by the parasite marks a significant divergence from its host in terms of spatiotemporal regulation by the Rab GTPases.

title: Insights into endosomal maturation of @entity1 holo- @entity69 in the enteric parasite XXXX : essential roles of @entity27341 and @entity4814 in biogenesis of giant early endocytic vacuoles.

answer: @entity2330 :: (5759,Species) :: ['Entamoeba histolytica']


abstract: UNASSIGNED: The pathogenic amoeba @entity2330 is one of the causative agents of health hazards in tropical countries. It causes @entity16126 , @entity1960 and @entity5572 in @entity1 . @entity68 is one of the essential nutritional resources for survival and @entity281 caused by the amoeba. The parasite has developed multiple ways to import, sequester and utilize @entity68 from various @entity68 -binding proteins from its host. In spite of its central role in pathogenesis, the mechanism of @entity68 uptake by the parasite is largely unknown. Here, we carried out a systematic study to understand the role of some of the amoebic homologues of @entity1 endocytic Rab GTPases ( @entity4814 and @entity38148 , @entity27341 and @entity21219 ) in intracellular transport of @entity1 holo- @entity69 by the parasite. Flow cytometry and quantitative microscopic image analysis revealed that @entity4814 and @entity27341 are required for the biogenesis of amoebic giant endocytic vacuoles (GEVs) and regulate the early phase of intracellular trafficking of @entity69 . @entity21219 is involved in the late phase, leading to the degradation of @entity69 in the amoebic lysosome-like compartments. Using time-lapse fluorescence imaging in fixed trophozoites, we determined the kinetics of the vesicular transport of @entity69 through @entity4814 -, @entity27341 - and @entity21219 -positive compartments. The involvement of @entity27341 in the early phase of endocytosis by the parasite marks a significant divergence from its host in terms of spatiotemporal regulation by the Rab GTPases.

title: Insights into endosomal maturation of XXXX holo- @entity69 in the enteric parasite @entity2330 : essential roles of @entity27341 and @entity4814 in biogenesis of giant early endocytic vacuoles.

answer: @entity1 :: (9606,Species) :: ['human']


abstract: Naegleria fowleri causes acute and fulminant primary amoebic @entity5422 . This microorganism invades its host by penetrating the olfactory mucosa and then traveling up the mesaxonal spaces and crossing the cribriform plate; finally, the trophozoites invade the olfactory bulbs. During its invasion, the protozoan obtains nutrients such as proteins, lipids, @entity3363 , and cationic ions (e.g., @entity68 , @entity460 , and @entity1372 ) from the host. However, the mechanism by which these ions are obtained, particularly @entity68 , is poorly understood. In the present study, we evaluated the ability of N. fowleri to degrade @entity68 -binding proteins, including hololactoferrin, @entity69 , ferritin, and hemoglobin. Zymography assays were performed for each substrate under physiological conditions (pH 7 at 37  C) employing @entity558 ( @entity558 ) and total crude extracts (TCEs) of N. fowleri. Different degradation patterns with @entity558 were observed for hololactoferrin, @entity69 , and hemoglobin; however, @entity558 did not cause ferritin degradation. In contrast, the TCEs degraded only hololactoferrin and @entity69 . Inhibition assays revealed that @entity462 proteases were involved in this process. Based on these results, we suggest that @entity558 and TCEs of N. fowleri degrade @entity68 -binding proteins by employing @entity462 proteases, which enables the parasite to obtain @entity68 to survive while invading the central nervous system.

title: XXXX -Binding Protein Degradation by @entity462 Proteases of Naegleria fowleri.

entities_list: @entity558 :: ('MESH:C536528', 'Disease') :: ['CM', 'conditioned medium']

entities_list: @entity462 :: ('MESH:D003545', 'Chemical') :: ['cysteine']

entities_list: @entity5422 :: ('MESH:D008590', 'Disease') :: ['meningoencephalitis']

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']

entities_list: @entity3363 :: ('MESH:D002241', 'Chemical') :: ['carbohydrates']

answer: @entity68 :: (MESH:D007501,Chemical) :: ['Iron']


abstract: Naegleria fowleri causes acute and fulminant primary amoebic @entity5422 . This microorganism invades its host by penetrating the olfactory mucosa and then traveling up the mesaxonal spaces and crossing the cribriform plate; finally, the trophozoites invade the olfactory bulbs. During its invasion, the protozoan obtains nutrients such as proteins, lipids, @entity3363 , and cationic ions (e.g., @entity68 , @entity460 , and @entity1372 ) from the host. However, the mechanism by which these ions are obtained, particularly @entity68 , is poorly understood. In the present study, we evaluated the ability of N. fowleri to degrade @entity68 -binding proteins, including hololactoferrin, @entity69 , ferritin, and hemoglobin. Zymography assays were performed for each substrate under physiological conditions (pH 7 at 37  C) employing @entity558 ( @entity558 ) and total crude extracts (TCEs) of N. fowleri. Different degradation patterns with @entity558 were observed for hololactoferrin, @entity69 , and hemoglobin; however, @entity558 did not cause ferritin degradation. In contrast, the TCEs degraded only hololactoferrin and @entity69 . Inhibition assays revealed that @entity462 proteases were involved in this process. Based on these results, we suggest that @entity558 and TCEs of N. fowleri degrade @entity68 -binding proteins by employing @entity462 proteases, which enables the parasite to obtain @entity68 to survive while invading the central nervous system.

title: @entity68 -Binding Protein Degradation by XXXX Proteases of Naegleria fowleri.

answer: @entity462 :: (MESH:D003545,Chemical) :: ['Cysteine']


abstract: Atherogenic properties of low density lipoproteins (LDL) in vivo may reflect modification of lipoproteins associated with endothelial translocation and exposure to extracellular matrix and interstitial fluid. To examine whether modifications of LDL occur in vivo, lipoproteins were isolated from plasma and vascular tissue of @entity8577 ( @entity8577 ) @entity95 . LDL was extracted from vascular tissue (LDL-V) by homogenization in the presence of a @entity1043 buffer. Control experiments demonstrated that modifications did not occur under the preparative conditions used to release LDL from tissue. LDL-V contained less esterified @entity165 , but more @entity8557 , than did LDL from plasma (LDL-P). The diameters of both LDL-V and LDL-P followed gaussian distributions, but LDL-V particles were smaller (20.3 +/- 0.1 and 26.3 +/- 0.1 nm). Mild lipid peroxidation was evident in LDL-V. The @entity4291 content was increased in LDL-V, with less @entity2434 than in LDL-P. Sodium dodecyl @entity597 - @entity2975 gel electrophoresis ( @entity214 -PAGE) indicated that @entity59386 was depleted in LDL-V, but Western blot analyses identified lower molecular weight proteins antigenically related to @entity59386 . LDL-V markedly stimulated @entity165 esterification in @entity19 peritoneal macrophages and also in @entity95 alveolar macrophages, a cell type that did not respond to acetylated LDL. LDL-V was not recognized by cultured @entity95 skin fibroblasts. Thus, LDL isolated from atherosclerotic vascular tissue in vivo was modified in a fashion that could confer atherogenic properties reflected by augmentation of @entity165 esterification in macrophages in vitro.

title: Isolation of low density lipoprotein from atherosclerotic vascular tissue of @entity8577 XXXX .

entities_list: @entity4291 :: ('CHEBI:17636', 'Chemical') :: ['sphingomyelin']

entities_list: @entity95 :: ('9986', 'Species') :: ['rabbits', 'rabbit']

entities_list: @entity8577 :: ('MESH:D065627', 'Disease') :: ['Watanabe heritable hyperlipidemic', 'WHHL']

entities_list: @entity2434 :: ('MESH:D010713', 'Chemical') :: ['phosphatidylcholine']

entities_list: @entity2975 :: ('CHEBI:51135', 'Chemical') :: ['polyacrylamide']

entities_list: @entity1043 :: ('MESH:C005686', 'Chemical') :: ['sodium carbonate']

entities_list: @entity8557 :: ('MESH:D002788', 'Chemical') :: ['cholesterol esters']

entities_list: @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']

entities_list: @entity597 :: ('CHEBI:16189', 'Chemical') :: ['sulfate']

answer: @entity95 :: (9986,Species) :: ['rabbits']


abstract: Atherogenic properties of low density lipoproteins (LDL) in vivo may reflect modification of lipoproteins associated with endothelial translocation and exposure to extracellular matrix and interstitial fluid. To examine whether modifications of LDL occur in vivo, lipoproteins were isolated from plasma and vascular tissue of @entity8577 ( @entity8577 ) @entity95 . LDL was extracted from vascular tissue (LDL-V) by homogenization in the presence of a @entity1043 buffer. Control experiments demonstrated that modifications did not occur under the preparative conditions used to release LDL from tissue. LDL-V contained less esterified @entity165 , but more @entity8557 , than did LDL from plasma (LDL-P). The diameters of both LDL-V and LDL-P followed gaussian distributions, but LDL-V particles were smaller (20.3 +/- 0.1 and 26.3 +/- 0.1 nm). Mild lipid peroxidation was evident in LDL-V. The @entity4291 content was increased in LDL-V, with less @entity2434 than in LDL-P. Sodium dodecyl @entity597 - @entity2975 gel electrophoresis ( @entity214 -PAGE) indicated that @entity59386 was depleted in LDL-V, but Western blot analyses identified lower molecular weight proteins antigenically related to @entity59386 . LDL-V markedly stimulated @entity165 esterification in @entity19 peritoneal macrophages and also in @entity95 alveolar macrophages, a cell type that did not respond to acetylated LDL. LDL-V was not recognized by cultured @entity95 skin fibroblasts. Thus, LDL isolated from atherosclerotic vascular tissue in vivo was modified in a fashion that could confer atherogenic properties reflected by augmentation of @entity165 esterification in macrophages in vitro.

title: Isolation of low density lipoprotein from atherosclerotic vascular tissue of XXXX @entity95 .

answer: @entity8577 :: (MESH:D065627,Disease) :: ['Watanabe heritable hyperlipidemic']


abstract: UNASSIGNED: Folate receptors a (FRa) and b (FRb) are two isoforms of the cell surface glycoprotein that binds @entity1501 . The expression of FRa is rare in normal cells and elevated in @entity5 cells. Thus, FRa-based @entity5 -targeted therapy has been a focus area of laboratory research and clinical trials. Recently, it was shown that a significant fraction of @entity5 -associated macrophages expresses FRb and that these cells can enhance @entity5 growth. Although FRa and FRb share 70% identity in their deduced @entity3689 sequence, a monoclonal antibody (MAb) reactive with both receptors has not been developed. A MAb that can target both FRa-expressing @entity5 cells and FRb-expressing @entity5 -associated macrophages may provide a more potent therapeutic tool for @entity5 than individual anti-FRa or anti-FRb MAbs. In this study, we developed a MAb that recognizes both FRa and FRb (anti-FRab). The anti-FRab specifically stained trophoblasts and macrophages from @entity1 placenta, synovial macrophages from @entity309 @entity1 , liver macrophages from @entity5434 and @entity7533 , and @entity5 cells and @entity5 -associated macrophages from @entity2 . Surface plasmon resonance showed that the anti-FRab bound to soluble forms of the FRa and FRb proteins with high affinity ( @entity573 =6.26*10(-9)   M and 4.33*10(-9)   M, respectively). In vitro functional analysis of the anti-FRab showed that this MAb mediates complement-dependent @entity137 , antibody-dependent cellular @entity137 , and antibody-dependent cellular phagocytosis of FRa-expressing and FRb-expressing cell lines. The anti-FRab MAb is a promising therapeutic candidate for @entity5 in which macrophages promote @entity5 progression.

title: Production of a High-affinity Monoclonal Antibody Reactive with XXXX Receptors Alpha and Beta.

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patient']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['cytotoxicity']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancers', 'cancer']

entities_list: @entity5434 :: ('9541', 'Species') :: ['cynomolgus monkey']

entities_list: @entity2 :: ('MESH:D008175', 'Disease') :: ['ovary and lung carcinomas']

entities_list: @entity7533 :: ('9483', 'Species') :: ['common marmoset']

entities_list: @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid arthritis']

answer: @entity1501 :: (MESH:D005492,Chemical) :: ['Folate']